AstraZeneca has halted its planned £200 ($270) million investment in a research facility in Cambridge, UK, according to reports from Reuters.  The investment, which was anticipated to generate 1,000 new jobs, is currently on hold.  The pharmaceutical company's decision indicates that none of its newly announced funding, initially revealed in March 2024, is moving forward […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!